Additional file 3: Figure S2. of Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study

Abstract

ACR20 response rate and mean DAS28‑4(ESR) and HAQ-DI over time for patients treated with tofacitinib 5 mg BID and tofacitinib 10 mg BID. (PDF 176 kb